Orgotein
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Orgotein
- DrugBank Accession Number
- DB11444
- Background
Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage. Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide radical into either the less damaging hydrogen peroxide or molecular oxygen. Hydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum.
- Type
- Biotech
- Groups
- Investigational, Vet approved
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Ontosein
- Orgotein
- Ormetein
- Palosein
- Superoxide dismutase (bovine)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- ATC Codes
- M01AX14 — Orgotein
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Musculo-Skeletal System
- Peripheral Nervous System Agents
- Proteins
- Sensory System Agents
- Superoxide Dismutase
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PKE82W49V1
- CAS number
- 1569268-91-2
References
- General References
- Lund-Olesen K: Intrathecal orgotein. Int J Clin Pharmacol Res. 1985;5(1):59-62. [Article]
- Mariani G: [Clinical experimentation with orgotein]. Clin Ter. 1986 Mar 15;116(5):373-5. [Article]
- Fischer CA: Orgotein and canine cataracts. J Am Vet Med Assoc. 1979 Aug 1;175(3):248-50. [Article]
- Boccafoschi C, Montefiore F: [Orgotein and La Peyronie's disease]. Minerva Urol Nefrol. 1987 Apr-Jun;39(2):125-8. [Article]
- Faull GL, de B Baker B, Walt HS, Hofmeyr CF: Clinical trials with orgotein (Palosein). J S Afr Vet Assoc. 1976 Mar;47(1):39-40. [Article]
- Goebel KM, Storck U, Neurath F: Intrasynovial orgotein therapy in rheumatoid arthritis. Lancet. 1981 May 9;1(8228):1015-7. [Article]
- Huskisson EC, Scott J: Orgotein in osteoarthritis of the knee joint. Eur J Rheumatol Inflamm. 1981;4(2):212-8. [Article]
- Decker WE, Edmondson AH, Hill HE, Holmes RA, Padmore CL, Warren HH, Wood WC: Local administration of orgotein in horses. Mod Vet Pract. 1974 Oct;55(10):773-4. [Article]
- Menander-Huber KB: Orgotein in the treatment of rheumatoid arthritis. Eur J Rheumatol Inflamm. 1981;4(2):201-11. [Article]
- Joral A, Boyano T, Mira J, Agud JL, Saiz F: Systemic anaphylaxis following parenteral orgotein administration. J Investig Allergol Clin Immunol. 1993 Mar-Apr;3(2):103-4. [Article]
- External Links
- 32526
- Wikipedia
- Superoxide_dismutase
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at February 25, 2016 18:49 / Updated at June 30, 2023 06:40